Aberrant Immune Cell Targeting via Bait-Payload Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders, such as biologic therapies and immunosuppressants, often come with significant drawbacks including toxicity, low response rates, and increased risks of infections and malignancies, highlighting an unmet need for more selective and effective therapies and diagnostic markers.
Innovation Solution
Development of compounds that selectively target aberrant immune cells by binding to enzymes or receptors overexpressed on these cells, using a 'Bait' moiety attached to a therapeutic 'Payload' to reduce or inhibit aberrant immune cell activity, thereby treating immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective immunosuppressants are used to treat immune disorders, then immune system activity is suppressed, but toxicity to normal cells and loss of immune function occurs
Solution Approach 1:
The patent applies local quality by designing compounds with distinct functional regions: a targeting moiety that specifically binds to aberrant immune cells and a therapeutic moiety that delivers the immunosuppressive effect. This ensures that suppression is localized to pathogenic cells while sparing normal immune cells, resolving the contradiction between efficacy and toxicity.
Solution Approach 2:
The invention segments the therapeutic compound into separate functional components: a targeting portion (antibody, antibody fragment, or ligand) and a therapeutic portion (immunosuppressant or cytotoxic agent). This segmentation allows independent optimization of targeting specificity and therapeutic activity, enabling selective suppression of aberrant immune cells without affecting normal cells.
2Object-affected harmful factors
If biologic therapies with high selectivity are used, then specific immune pathways are modulated, but response rates remain low and combination therapy increases complexity
Solution Approach 1:
The patent employs parameter changes by modifying the therapeutic moiety's properties (such as using different classes of immunosuppressants or cytotoxic agents with varying mechanisms of action) to optimize the balance between selectivity and response rate. This allows tuning of the therapeutic effect to achieve both high selectivity and improved response rates.
3Reliability
If antibody therapies are administered at standard doses, then therapeutic effect is achieved, but administration time becomes excessively long
Solution Approach 1:
The invention merges the targeting function and therapeutic function into a single conjugate molecule, eliminating the need for separate administration steps. This integration maintains therapeutic efficacy while dramatically reducing administration time compared to traditional antibody therapies that require separate dosing regimens.
4Reliability
If B-cell depleting therapies are used, then autoimmune activity is reduced, but risk of infections and malignancies increases
Solution Approach 1:
The patent applies local quality by directing the therapeutic effect specifically to aberrant B-cells through selective targeting, rather than depleting all B-cells systemically. This localized approach controls autoimmune activity while preserving normal B-cell functions, thereby reducing the risk of infections and malignancies associated with broad B-cell depletion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively target and reduce aberrant immune cell activity, offering a more selective and potentially safer treatment option for autoimmune disorders, with specific examples demonstrating antiproliferative activity in immune cells stimulated by autoimmune patient plasma.
Implementation Method 1
a ligand that binds an enzyme or receptor that is overexpressed on a surface of the aberrant immune cell
Implementation Method 2
a therapeutic moiety that reduces or inhibits an activity of the enzyme or receptor
Data Source
AI summary
Disclosed are compositions and methods of treating and diagnosing immune-related disorders characterized by the presence of aberrant immune cells that over-express certain proteins or that express a protein not expressed on normal immune cells.